The British based global pharmaceutical company, AMCo, is to be bought by the Canadian healthcare business Concordia
Pharmaceutical company, AMCo, is to be bought by Concordia
Concordia is a healthcare company focused on legacy pharmaceutical products and orphan drugs.
The acquisition creates an international pharmaceutical company, with products available in over 100 countries and operations in many of the major pharmaceutical markets in the world.
John Beighton, chief executive officer of AMCo, commented: “We look forward to being part of the Concordia business.
“We believe everyone will benefit and that it will increase patients’ access to medicines. We have a shared vision for growth that should greatly benefit employees and stakeholders of the combined business.”
Mark Thompson, Concordia’s chairman and chief executive officer, said: “We are not only acquiring products and commercial infrastructure, but a seasoned management team who has done a fantastic job of building a solid and successful international operation.
“The combination of our highly complementary yet geographically diverse businesses is truly transformational.”